Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 - Pruneri, G; Gray, K P; Vingiani, A (Breast Cancer Res Treat, 2016)